Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4374 participants.
Also called NCT06108414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 4,374 participants
- Registry
-
NCT06108414
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06108414. Randomized; single masking; primary purpose treatment. Start 2024-09-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Condition
- Anticoagulant Adverse Reaction
- Condition
- Stroke
- Condition
- Major Adverse Cardiac Events
- Intervention (Drug)
- low-dose rivaroxaban
- Intervention (Drug)
- Standard-dose rivaroxaban
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct06108414- Content hash
b3dea0ba498c9d081e677fdc2c769f083062155e0c06f511f41dd9f422c37292